Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04144036 · ClinicalTrials.gov registry record · Phase 1
Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)
A Phase 1 study, sponsored by Sameem M. Abedin, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04144036 is a Phase 1 study that has completed, run by Sameem M. Abedin, MD. The registered enrollment target is 12 participants.
The verdict
NCT04144036, a Phase 1 study, has completed, sponsored by Sameem M. Abedin, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a single-center Phase I study to determine the maximum tolerated dose and safety of Neihulizumab for the treatment of Minnesota standard-risk aGVHD. Patients undergoing allogeneic transplant with either a myeloablative or non-myeloablative conditioning regimen, and recipients of all donor sources will be enrolled to this trial.
Interventions
- BIOLOGICAL Neihulizumab, 3 mg/kg
- DRUG Neihulizumab, 6 mg/kg
- DRUG Neihulizumab, 9 mg/kg
- DRUG Neihulizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2024-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04144036
The ClinicalTrials.gov registry entry for NCT04144036 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sameem M. Abedin, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Neihulizumab, 3 mg/kg is the first listed.
NCT04144036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04144036 about?
NCT04144036 is a clinical study titled "Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)". This is a single-center Phase I study to determine the maximum tolerated dose and safety of Neihulizumab for the treatment of Minnesota standard-risk aGVHD. Patients undergoing allogeneic transplant with either a myeloablative or non-myeloablative conditioning regimen, and recipients of all donor so...
What is the current status of trial NCT04144036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-12-14. Estimated completion is 2024-07-07.
What interventions are being tested in trial NCT04144036?
The interventions under investigation include: Neihulizumab, 3 mg/kg (BIOLOGICAL), Neihulizumab, 6 mg/kg (DRUG), Neihulizumab, 9 mg/kg (DRUG), Neihulizumab (DRUG).
Who is sponsoring clinical trial NCT04144036?
This trial is sponsored by Sameem M. Abedin, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.